Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer

NCT07009600 | Completed

• 1 other identifier: SMC 2025-03-046-001
• Study Type: observational
• Target: 124
• Locations: 0 countries
• Sites: N/A

Brief Summary

In this retrospective study, investigators conducted a comprehensive investigation of the factors influencing postoperative prognosis in patients with stage IV gastric cancer undergoing conversion surgery. Specifically, investigators examined the impact of targeted therapy or immune check point inhibitors (ICIs) in combination with preoperative chemotherapy on (1) prognostic differences based on initial progression (invading adjacent organs) and metastatic site (peritoneum, distant lymph node \[LN\]) at the time of stage IV gastric cancer diagnosis and (2) conversion surgery outcomes and pathological complete response (pCR).

Conditions

Gastric Cancer Stage IV

Outcome Measures

Primary Outcomes (1)

• overall survival and disease free survival

  from date of surgery until the date of first documented cancer recurrence or date of death from cancer progression, whichever came first, assessed up to 160 months

Interventions

immune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab) DRUG

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with clinically diagnosed and histologically confirmed stage IV gastric cancer between January 2010 and August 2024 and received systemic palliative-intent chemotherapy as initial treatment and underwent conversion surgery at Samsung Medical Center.

You may qualify if:

• Stage IV gastric cancer patients who underwent conversion surgery

You may not qualify if:

• Patients who did not undergo gastrectomy
• Patients who underwent emergent surgery due to cancer perforation
• Patients with missing medical records or information

Sponsors & Collaborators

• Samsung Medical Center: lead

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

Immune Checkpoint Inhibitors; Trastuzumab

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Intervention Hierarchy (Ancestors)

Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Antineoplastic Agents, Immunological; Antineoplastic Agents; Therapeutic Uses; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical assistant professor

Study Record Dates

• First Submitted: May 23, 2025
• First Posted: June 6, 2025
• Study Start: January 1, 2010
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: June 6, 2025

Record last verified: 2025-06